GlassScriptPhysician profile
Riquel Gonzalez
NPI 1457693566
$52,457.01
in general payments reported to CMS, 2019-2025
39 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 81% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $2,955 · 2021: $1,797 · 2022: $13K · 2023: $23K · 2024: $8,673 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $11K · Food and Beverage: $2,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,428.75 |
| Travel and Lodging | $11,177.33 |
| Food and Beverage | $2,760.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vilex LLC | $40,031.88 | 2022-2024 | |
| Musculoskeletal Transplant Foundation INC. | $3,192.10 | 2019-2022 | |
| Arthrex, INC. | $1,567.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,137.49 | 2025 | |
| Hnm Total Recon | $1,077.82 | 2021 | |
| Hnm Stainless, LLC | $839.07 | 2022-2025 | |
| Stryker Corporation | $806.08 | 2019-2025 | Salvation, Augment Injectable, Valor |
| Southern Edge Orthopaedics, INC. | $637.00 | 2019 | |
| Organogenesis INC. | $617.84 | 2020-2024 | Puraply, Puraply Antimicrobial |
| Smith+Nephew, INC. | $432.07 | 2019-2025 | Grafix Pl, Stravix, Oasis |
| Paragon 28, INC. | $330.81 | 2021-2025 | Trauma |
| Wright Medical Technology, INC. | $261.93 | 2019 | |
| Treace Medical Concepts, INC. | $190.23 | 2024 | |
| Kerecis Limited | $158.04 | 2019-2021 | |
| Royal Biologics, INC. | $130.18 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $118.81 | 2022 | |
| In2bones USA, LLC | $118.46 | 2019 | |
| Biotissue Holdings INC. | $107.86 | 2022-2025 | |
| Bioventus LLC | $106.04 | 2019-2022 | |
| Medela LLC | $91.03 | 2019 | |
| Integra Lifesciences Corporation | $87.50 | 2020 | |
| Melinta Therapeutics, LLC | $50.24 | 2019 | |
| Horizon Therapeutics Plc | $40.41 | 2021 | |
| Embody, INC. | $39.33 | 2021 | |
| Biocomposites INC | $37.59 | 2019 | |
| Heron Therapeutics, INC. | $37.00 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $29.85 | 2019 | |
| Amniox Medical, INC. | $22.90 | 2019 | |
| Abbott Laboratories | $20.88 | 2023 | Eterna |
| Amgen INC. | $20.72 | 2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $19.23 | 2023 | Nuzyra |
| Misonix INC | $19.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2022 | |
| Kci USA, INC. | $17.14 | 2023 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Acell, INC. | $17.01 | 2019 | |
| Stimwave Technologies Incorporated | $16.25 | 2020 | |
| Pfizer INC. | $10.94 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riquel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.